<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6844378</article-id><article-id pub-id-type="pmid">31690133</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1684911</article-id><article-id pub-id-type="publisher-id">1684911</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Structure activity relationship studies on Amb639752: toward the
identification of a common pharmacophoric structure for DGK&#x003b1; inhibitors</article-title><alt-title alt-title-type="running-authors">S. Velnati et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Velnati</surname><given-names>Suresh</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>b</sup>
</xref><xref ref-type="author-notes" rid="FN0001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Massarotti</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref><xref ref-type="author-notes" rid="FN0001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Antona</surname><given-names>Annamaria</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Talmon</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fresu</surname><given-names>Luigia Grazia</given-names></name><xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Galetto</surname><given-names>Alessandra Silvia</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="aff" rid="AF0005">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Capello</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bertoni</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mercalli</surname><given-names>Valentina</given-names></name><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Graziani</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0006">
<sup>f</sup>
</xref><xref ref-type="aff" rid="AF0007">
<sup>g</sup>
</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Tron</surname><given-names>Gian Cesare</given-names></name><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref><xref ref-type="author-notes" rid="FN0002"/><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><name><surname>Baldanzi</surname><given-names>Gianluca</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>b</sup>
</xref><xref ref-type="author-notes" rid="FN0002"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Translational Medicine,
University of Piemonte Orientale</institution>, Novara, <country>Italy</country>; </aff><aff id="AF0002"><label>b</label><institution>Institute for Research and Cure of Autoimmune
Diseases, CAAD, University of Piemonte Orientale</institution>, Novara,
<country>Italy</country>; </aff><aff id="AF0003"><label>c</label><institution>Department of Pharmaceutical Sciences,
University of Piemonte Orientale</institution>, Novara, <country>Italy</country>; </aff><aff id="AF0004"><label>d</label><institution>Department of Health Sciences, School of
Medicine, University of Piemonte Orientale</institution>, Novara,
<country>Italy</country>; </aff><aff id="AF0005"><label>e</label><institution>Palliative Care Division,
A.S.L.</institution>, Vercelli, <country>Italy</country>; </aff><aff id="AF0006"><label>f</label><institution>Universit&#x000e0; Vita-Salute San
Raffaele</institution>, Milan, <country>Italy</country>; </aff><aff id="AF0007"><label>g</label><institution>Department of Molecular Biotechnology and
Health Sciences, Molecular Biotechnology Center, University of Torino</institution>,
Turin, <country>Italy</country></aff></contrib-group><author-notes><fn id="FN0001"><label>*</label><p>These authors contributed equally to this work.</p></fn><fn id="FN0002"><p>&#x02020;These authors shared senior authorship.</p></fn><fn id="AUFN3"><p>Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1684911"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Andrea Graziani
<email>andrea.graziani@hsr.it</email><institution>Universit&#x000e0; Vita-Salute San Raffaele</institution>, Milan 20132,
<country>Italy</country>; </corresp><corresp id="AN0002">Gian Cesare Tron <email>giancesare.tron@uniupo.it</email><institution>Department of Pharmaceutical Science, University of Piemonte
Orientale</institution>, Novara 28100, <country>Italy</country></corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2019</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="10">96</fpage><lpage>108</lpage><history><date date-type="received"><day>08</day><month>8</month><year>2019</year></date><date date-type="rev-recd"><day>21</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as
Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1684911.pdf"/><abstract><title>Abstract</title><p>A series of analogues of Amb639752, a novel diacylglycerol kinase (DGK) inhibitor
recently discovered by us via virtual screening, have been tested. The compounds were
evaluated as DGK inhibitors on &#x003b1;, &#x003b8;, and &#x003b6; isoforms, and as antagonists on serotonin
receptors. From these assays emerged two novel compounds, namely <bold>11</bold> and
<bold>20</bold>, which with an IC<sub>50</sub> respectively of 1.6 and 1.8&#x000a0;&#x000b5;M are the
most potent inhibitors of DGK&#x003b1; discovered to date. Both compounds demonstrated the ability
to restore apoptosis in a cellular model of X-linked lymphoproliferative disease as well
as the capacity to reduce the migration of cancer cells, suggesting their potential
utility in preventing metastasis. Finally, relying on experimental biological data,
molecular modelling studies allow us to set a three-point pharmacophore model for DGK
inhibitors.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Diacylglycerol kinase</kwd><kwd>kinase inhibitors</kwd><kwd>structure&#x02013;activity relationship</kwd><kwd>enzyme assays</kwd><kwd>molecular modelling</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">Universit&#x000e0; del Piemonte
Orientale</named-content><named-content content-type="funderidentifier">10.13039/501100005699</named-content></funding-source></award-group><award-group><funding-source><named-content content-type="funder-name">Telethon Foundation</named-content></funding-source><award-id>GGP16252</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">National Ministry of University and Research
PRIN 2017</named-content></funding-source><award-id>201799WCRH</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Consorzio Interuniversitario di Biotecnologie
(CIB) bando &#x0201c;Network-CIB: Catalisi dell&#x02019;Innovazione nelle
biotecnologie&#x0201d;</named-content></funding-source></award-group><funding-statement>This work was supported by Universit&#x000e0; del Piemonte Orientale, Telethon
Foundation [Grant GGP16252 to AG and GB], National Ministry of University and Research
PRIN 2017 [Grant 201799WCRH to GB], Consorzio Interuniversitario di Biotecnologie (CIB)
bando &#x0201c;Network-CIB: Catalisi dell&#x02019;Innovazione nelle biotecnologie&#x0201d; to
GB.</funding-statement></funding-group><counts><fig-count count="11"/><table-count count="2"/><page-count count="13"/><word-count count="8568"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><p>Diacylglycerol kinases (DGKs) are a large family of enzymes that share a common catalytic
activity: the phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PA). Remarkably,
both the substrate (DAG) and the product (PA) of the DGK-catalysed reaction, are bioactive
lipids that can act as second messengers<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. DGK activity consequently serves as a switch to simultaneously
dampen DAG-mediated signals and boost PA-mediated signals<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Ten mammalian DGK isoforms (&#x003b1;, &#x003b2;, &#x003b3;, &#x003b4;, &#x003b5;, &#x003b6;, &#x003b7;, &#x003b8;, &#x003b9;, and &#x0043a;) have
been identified and divided into five groups (type I&#x02013;V) according to their structural
features<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>. The expression of these isoforms varies
depending on the cell type. Among the 10 isoforms, the &#x003b1; isoform is among the most studied
and characterised. This kinase is highly expressed in the brain, spleen, and thymus and,
along with &#x003b8; isoform, in the bone marrow. This enzyme is also highly expressed in
T-lymphocytes, where it acts together with DGK&#x003b6; as negative regulator of the T-cell receptor
(TCR) response, and a mediator of IL-2 mediated proliferation<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. The biological relevance of DGK&#x003b1; is best demonstrated in patients
with X-linked lymphoproliferative disease (XLP-1), who experience life-threatening,
uncontrolled accumulation of CD8<sup>+</sup> T cells in response to the Epstein&#x02013;Barr virus
(EBV) infection<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. In those patients,
germline mutations of the adaptor protein SAP (SH2D1A) perturb TCR signalling and render
DGK&#x003b1; constitutively active<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>.
Deregulated DGK&#x003b1; activity renders patient-derived lymphocytes resistant to
reactivation-induced cell death (RICD). Thus, antigen-activated lymphocytes accumulate in
lymphonodes and liver, resulting in severe immunopathology<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. Importantly, DGK&#x003b1; inhibitors restore RICD sensitivity
<italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic>, thus avoiding immunopathology and
suggesting a putative therapeutic use of those molecules in XLP-1<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>.</p><p>Apart from T-cell regulation, DGK&#x003b1; also plays a role in cancer, mediating numerous aspects
of cancer cell progression including survival<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>, migration and invasion of cancer cells<xref rid="CIT0012" ref-type="bibr"><sup>12&#x02013;14</sup></xref>. In particular, it has been reported
that DGK&#x003b1; is over expressed in hepatocellular carcinoma<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>, and melanoma cells<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref> while other reports suggested that the growth of colon and breast
cancer cell lines was significantly inhibited by DGK&#x003b1;-siRNA<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref> and DGK&#x003b1;/atypical PKC/&#x003b2;1 integrin signalling pathway
was crucial for matrix invasion of breast carcinoma cells<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>. In addition, expression is also higher in lymphonodal metastasis
than in breast and gastric original tumour<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>.
Finally, knock down of DGK&#x003b1; impairs glioblastoma tumorigenesis<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>.</p><p>For all these reasons, the identification of strong and selective DGK&#x003b1; inhibitors, it is an
important field of research. To date, only a handful of two-digit micromolar inhibitors of
DGK&#x003b1; have been identified, but only three were the most characterised, namely, R59949,
R59022, and ritanserin (<xref ref-type="fig" rid="F0001">Figure 1)</xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Three of the most studied DGK&#x003b1; inhibitors.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0001_B"/></fig><p>In our assay system, R59949 and R59022 have an IC<sub>50</sub> of 11 and 20&#x000a0;&#x000b5;M,
respectively<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. Their efficacy has
been evaluated <italic>in&#x000a0;vivo</italic> studies on mice, and is limited by their rapid
clearance (<italic>t</italic><sub>1/2</sub>=&#x0223c;2&#x02009;h)<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. Furthermore, these two inhibitors are also able to target
different isoforms of DGK, in particular R59022 acts on type III and V (&#x003b5; e &#x003b8;), while R59949
on type I and II (&#x003b3;, &#x003b4; e &#x003ba;)<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>
and a study conducted by Boroda et&#x000a0;al. recently demonstrated their strong antagonistic
activity on 5-HT<sub>2</sub> receptors (R59022 IC<sub>50</sub> 5HT<sub>2A</sub>=2.2&#x02009;nM;
R5994 IC<sub>50</sub> 5HT<sub>2A</sub>=9.2&#x02009;nM)<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p><p>A search on ChEMBL database<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>
(<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</ext-link>) show how these two molecules have activity at
the same range of concentration with other biological targets, behaving like a sort of
promiscuous ligands. Ritanserin, a well-known serotoninergic antagonist, is structurally
similar to R59022, differing for an H-F isosteric substitution on a phenyl ring. Despite
this small modification, Boroda et&#x000a0;al. showed that ritanserin was a DGK&#x003b1; inhibitor
(IC<sub>50</sub>=15&#x02009;&#x000b5;M) more potent than R59022 and R59949 and with a better
pharmacokinetic profile (<italic>t</italic><sub>1/2</sub>=40&#x02009;h in human)<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. However, the comparison of ritanserin
IC<sub>50</sub> as serotonin antagonist and as DGK&#x003b1; inhibitor, 0.9&#x02009;nM and 15,000&#x02009;nM,
respectively, reveal that ritanserin is much a powerful serotonin antagonist than a DGK
inhibitor. In addition, ritanserin is also a potent inhibitor on dopaminergic receptors with
an IC<sub>50</sub> of 69&#x02009;nM<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>.</p><p>Due to these drawbacks, at the beginning, in order to eliminate the strong serotoninergic
activity of R59949, we reasoned to replace its protonable nitrogen atom, which at
physiologically pH mimics the amino group of serotonin, with a carbon atom. We decided
therefore to synthesise compound <bold>1</bold> (<xref ref-type="fig" rid="F0002">Figure
2</xref>) (see supporting information for its synthesis and a complete characterisation)
and to test it as DGK&#x003b1; inhibitor.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Structures of the deaza analogue of R59949 and Amb639752.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0002_B"/></fig><p>Interestingly, the compound was totally devoid of inhibitory activity on the enzyme,
showing the importance of the basic nitrogen atom not only for the anti-serotoninergic
activity, but also for the interaction with the kinase. With this in mind, we recently used
an in-silico approach based on chemical homology with the two commercially available DGK&#x003b1;
inhibitors R59022 and R59949 using the programmes ROCS<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref> and EON<xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>.
From this study, we identified a compound, Amb639752 (<xref ref-type="fig" rid="F0002">Figure 2</xref>), featuring a lower IC<sub>50</sub> for DGK&#x003b1; than ritanserin
(IC<sub>50</sub>=17&#x000a0;&#x000b5;M), a better selectivity for the &#x003b1;-isoform and devoid of
anti-serotoninergic activity. Along with CU-3, which features an IC<sub>50</sub> of 0.6&#x000a0;&#x000b5;M
on DGK&#x003b1;<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref> but contains a reactive
Michael acceptor<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>, Amb639752 is the
most effective pharmacological tool available to study DGK&#x003b1;<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. In this manuscript, we report the structure&#x02013;activity
studies on Amb639752 and, in combination with data on ritanserin, the generation of a
pharmacophore model for this class of compounds, which could be useful for the
identification of other potential DGK&#x003b1; inhibitors.</p></sec><sec id="s0002"><label>2.</label><title>Methods</title><sec id="s0003"><label>2.1.</label><title>Chemistry procedures</title><p>Commercially available reagents and solvents were used without further purification.
Toluene were distilled immediately before use from Na/benzophenone under a slight positive
atmosphere of dry nitrogen. Dichloromethane was dried by distillation from
P<sub>2</sub>O<sub>5</sub> and stored on activated molecular sieves (4&#x000a0;&#x000c5;). When needed
the reactions were performed in flame- or oven-dried glassware under a positive pressure
of dry nitrogen. Melting points were determined in open glass capillary with a Stuart
scientific SMP3 apparatus and are uncorrected. All compounds were checked by IR (FT-IR
THERMO-NICOLET AVATAR), <sup>1</sup>H and 13C APT (JEOL ECP 300&#x02009;MHz spectrometer), and
mass spectrometry (Thermo Finningan LCQ-deca XP-plus, San Jose, CA) equipped with an ESI
source and an ion trap detector. Chemical shifts are reported in parts per million (ppm).
Flash column chromatography was performed on silica gel (Merck Kieselgel 60, 230&#x02013;400&#x000a0;mesh
ASTM, Kenilworth, NJ). Thin layer chromatography (TLC) was carried out on 5&#x02009;&#x000d7;&#x02009;20&#x02009;cm plates
with a layer thickness of 0.25&#x02009;mm (Merck Silica gel 60 F<sub>254</sub>, Kenilworth, NJ).
When necessary they were developed with KMnO<sub>4</sub> reagent. Purity of tested
compounds was established by elemental analysis. Elemental analysis (C, H, N) of the
target compounds is within &#x000b1;0.4% of the calculated values, confirming &#x02265;95% purity.</p><sec id="s0004"><label>2.1.1.</label><title>Preparation of 2-chloro-1-(2,6-dimethyl-1H-indol-3-yl)ethan-1-one (5)</title><p>In a Schlenk tube, under nitrogen, 2,6-dimethyl-1<italic>H</italic>-indole
(<bold>3</bold>) (0.20&#x02009;g, 1.38&#x02009;mmol, 1&#x000a0;eq) was dissolved in 4&#x02009;mL of dichloroethane dry
and 0.25&#x02009;mL of DBU (1.66&#x02009;mmol, 1.2&#x000a0;eq) were added. The resulting solution was heated at
90&#x02009;&#x000b0;C. When reached this temperature, chloroacetyl chloride (<bold>4</bold>) (0.12&#x02009;mL,
1.52&#x02009;mmol, 1.1&#x000a0;eq) was added. The reaction was stirred for 30&#x02009;min, then solvent was
evaporated and the crude purified by column chromatography using PE/EtOAc 7:3 and
PE/EtOAc 5:5 as eluants to give 270&#x02009;mg of product as violet solid: yield 90%; m.p.
243.7&#x02013;244.2&#x02009;&#x000b0;C; <sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.88
(br s, NH), 7.85 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.18 (s, 1H), 6.99 (d,
<italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H), 4.89 (s, 2H), 2.68 (s, 3H), 2.39 (s, 3H). MS (ESI)
<italic>m/z</italic>: 222 [M&#x02009;+&#x02009;H]<sup>+</sup>.</p></sec><sec id="s0005"><label>2.1.2.</label><title>Preparation of tert-butyl
4-(2-(2,6-dimethyl-1H-indol-3-yl)-2-oxoethyl)piperazine-1-carboxylate (6)</title><p>Under nitrogen, 200&#x02009;mg of <bold>5</bold> (0.90&#x02009;mmol, 1&#x000a0;eq) was dissolved in toluene
dry, then <italic>N</italic>-Boc-piperazine (0.17&#x02009;g, 0.90&#x02009;mmol, 1&#x000a0;eq),
K<sub>2</sub>CO<sub>3</sub> (0.32&#x02009;g, 2.25&#x02009;mmol, 2.5&#x000a0;eq), and KI (0.015&#x02009;g, 0.09&#x02009;mmol,
0.1&#x000a0;eq) were added. The reaction was heated at 80&#x02009;&#x000b0;C overnight. Solvent was evaporated
and the crude was purified by column chromatography using PE/EtOAc 4:6 and PE/EtOAc 2:8
as eluants to give 215&#x02009;mg of product as yellow amorphous solid: yield 63%; <sup>1</sup>H
NMR (300&#x02009;MHz, CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 8.52 (br s, NH), 7.77 (d,
<italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.12 (s, 1H), 7.08 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz,
1H), 3.79 (s, 2H), 3.47&#x02013;3.43 (m, 6H), 2.75 (s, 3H), 2.64 (br s, 2H), 2.44 (s, 3H), 1.47
(s, 9H). IR (KBr): 3190, 2964, 1698, 1413, 1417, 1364, 1126, 806
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>. MS (ESI) <italic>m/z</italic>: 372
[M&#x02009;+&#x02009;H]<sup>+</sup>.</p></sec><sec id="s0006"><label>2.1.3.</label><title>Preparation of 1-(2,6-dimethyl-1H-indol-3-yl)-2-(piperazin-1-yl)ethan-1-one
(7)</title><p>Two hundred and fifteen milligrams of <bold>6</bold> (0.58&#x02009;mmol, 1&#x000a0;eq) were dissolved
in dichloromethane dry. The resulting solution was cooled at 0&#x02009;&#x000b0;C and 0.69&#x02009;mL of
trifluoroacetic acid (9.28&#x02009;mmol, 16&#x000a0;eq) was added. After 3&#x02009;h, the reaction was worked up
adding NaOH 2&#x000a0;M solution until pH = 12. Then, NaCl solid was added and the solution was
extracted with THF (x2). The combined organic phases were dried on sodium sulphate.
After evaporation of the solvent, the crude was purified by column chromatography using
EtOAc/MeOH 9:1 and MeCN/NH<sub>3</sub> 9:1 as eluants to give 103&#x02009;mg of the product as
yellowish solid: yield: 65%; m.p.: 232.9&#x02013;233.6&#x02009;&#x000b0;C; <sup>1</sup>H NMR (300&#x02009;MHz,
DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.79 (br s, NH), 7.85 (d,
<italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.15 (s, 1H), 6.95 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz,
1H), 3.83(br s, 4H), 3.62 (s, 2H), 2.86 (br s, 4H), 2.67 (s, 3H), 2.38 (s, 3H); IR
(KBr): 3446, 3181, 2813, 1634, 1455, 1330, 821
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI) <italic>m/z</italic>: 272
[M&#x02009;+&#x02009;H]<sup>+</sup>.</p></sec><sec id="s0007"><label>2.1.4.</label><title>General procedure for the synthesis of final compounds 8, 11&#x02013;22</title><p>1-(2,6-Dimethyl-1<italic>H</italic>-indol-3-yl)-2-(piperazin-1-yl)ethan-1-one
(<bold>7</bold>) (1&#x000a0;eq) was dissolved in dichloromethane dry. To the resulting
solution EDCI (1&#x000a0;eq), TEA (2&#x000a0;eq), DMAP (0.1&#x000a0;eq) and the appropriate carboxylic acid
(1&#x000a0;eq) were sequentially added. The reaction was stirred under nitrogen at room
temperature overnight. Evaporation of the solvent gave a crude which was directly
purified by column chromatography.</p></sec><sec id="s0008"><label>2.1.5.</label><title>2-(4-Benzoylpiperazin-1-yl)-1-(2,6-dimethyl-1H-indol-3-yl)ethan-1-one (8)</title><p>Yellow solid; yield 29%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 213.8&#x02013;214.3&#x02009;&#x000b0;C.
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.72 (br s, NH),
7.85 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.46&#x02013;7.40 (m, 5H), 7.15 (s, 1H), 6.96 (d,
<italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 3.67 (br s, 4H), 3.18 (br s, 2H) 2.67 (s, 3H),
2.61&#x02013;2.56 (m, 4H), 2.38 (s, 3H); <sup>13</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>)
<italic>&#x003b4;</italic> 192.8, 169.5, 144.7, 136.5, 135.7, 131.5, 130.0, 129.0, 127.5,
125.1, 123.4, 121.2, 112.9, 111.6, 66.9, 53.2, 53.1, 21.7, 15.7; IR (KBr) 3189, 2990,
2828, 1609, 1446, 1282, 807 <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>. MS (ESI)
<italic>m/z</italic>: 374 [M&#x02013;H]<sup>+</sup>. Anal. Calcd. for
C<sub>23</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>: C, 73.57; H, 6.71; N, 11.19;
found C, 73.76; H, 6.94; N, 10.85.</p></sec><sec id="s0009"><label>2.1.6.</label><title>2-(4-(4-Chlorobenzoyl)piperazin-1-yl)-1-(2,6-dimethyl-1H-indol-3-yl)ethan-1-one
(11)</title><p>Yellow solid; yield 33%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 240.7&#x02013;241.3&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.70 (br s, NH),
7.85 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.50 (br d, AA&#x02019;XX&#x02019;, 2H), 7.42 (br d, AA&#x02019;XX&#x02019;,
2H), 7.14 (s, 1H), 6.95 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 3.67 (br s, 4H), 3.33 (br
s), 2.67 (s, 3H), 2.61&#x02013;2.56 (m, 4H), 2.38 (s, 3H); <sup>13</sup>C NMR (75&#x02009;MHz,
DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 193.17, 168.4, 144.8, 135.7, 135.2, 134.8,
131.5, 129.5, 129.1, 125.1, 123.5, 121.2, 112.7, 111.6, 53.14, 53.14, 52.9, 21.7, 15.7.
IR (KBr): 3225, 2793, 2358, 1609, 1442, 1261, 864
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>. MS (ESI) <italic>m/z</italic>: 410
[M&#x02009;+&#x02009;H]<sup>+</sup>. Anal. Calcd. for C<sub>23</sub>H<sub>24</sub>
ClN<sub>3</sub>O<sub>2</sub>: C, 67.39; H, 5.90; N, 10.25; found C, 67.11; H, 6.12; N,
10.54.</p></sec><sec id="s0010"><label>2.1.7.</label><title>1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(4-methoxybenzoyl)piperazin-1-yl)ethan-1-one
(12)</title><p>Yellow solid; yield 53%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 219.9&#x02013;220.8&#x02009;&#x000b0;C.;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.70 (br s, NH),
7.85 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.38 (br d, AA&#x02019;XX&#x02019;, 2H), 7.14 (s, 1H),
6.99&#x02013;6.94 (m, 3H), 3.79 (br d, 3H), 3.67 (br s, 2H), 3.51 (br s, 4H) 2.67 (s, 3H), 2.58
(br s, 4H), 2.38 (s, 3H); <sup>13</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>)
<italic>&#x003b4;</italic> 192.8, 169.5, 144.6, 136.5, 135.7, 131.5, 130.0, 129.0, 127.5,
125.1, 123.4, 121.2, 112.8, 111.6, 66.9, 55.8, 53.2, 53.1, 21.7, 15.7; IR (KBr): 3235,
3003, 2807, 1613, 1463, 1253, 977 <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS
(ESI) <italic>m/z</italic>: 406 [M&#x02009;+&#x02009;H]<sup>+</sup>. Anal. Calcd. for
C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub>: C, 71.09; H, 6.71; N, 10.36;
found C, 71.10; H, 6.75; N, 10.32.</p></sec><sec id="s0011"><label>2.1.8.</label><title>4-(4-(2-(2,6-Dimethyl-1H-indol-3-yl)-2-oxoethyl)piperazine-1-carbonyl)benzonitrile
(13)</title><p>Yellow solid; yield 23%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 243.9&#x02013;244.8&#x02009;&#x000b0;C.
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.70 (br s, NH),
7.92&#x02013;7.84 (m, 3H), 7.58 (br d, AA&#x02019;XX&#x02019;, 2H), 7.15 (s, 1H), 6.96 (br d, 1H), 3.68 (br s,
4H), 3.29 (br s, 2H), 2.67 (s, 3H), 2.51 (br s, 4H), 2.38 (s, 3H); <sup>13</sup>C NMR
(75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 192.5, 166.3, 143.2, 139.4, 134.1,
131.6, 129.9, 126.8, 123.5, 121.9, 119.6, 117.4, 111.2, 111.1, 110.1, 65.1, 51.7, 51.2,
20.1, 14.1; IR (KBr): 3410, 3254, 2816, 2790, 2233, 1609, 1454, 1291, 979
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI) <italic>m/z</italic>:
401[M&#x02009;+&#x02009;H]<sup>+</sup>. Anal. Calcd. for
C<sub>24</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>: C, 71.98; H, 6.04; N, 13.99;
found C, 72.13; H, 6.23; N, 14.08.</p></sec><sec id="s0012"><label>2.1.9.</label><title>1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(thiophene-2-carbonyl)piperazin-1-yl)ethan-1-one
(14)</title><p>Yellow solid; yield 29%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 200.3&#x02013;201.2&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.74 (br s, NH),
7.86 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.76 (br d, 1H), 7.41&#x02013;7.40 (m, 1H), 7.15&#x02013;7.10
(m, 2H), 6.96 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 3.75&#x02013;3.67 (m, 4H), 3.37 (br s, 2H)
2.68 (s, 3H), 2.62 (s, 4H), 2.38 (s, 3H); <sup>13</sup>C NMR (75&#x02009;MHz,
DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 192.8, 167.8, 144.7, 137.8, 135.7, 131.5, 130.0,
129.6, 127.7, 125.1, 124.1, 123.4, 121.2, 112.8, 111.6, 66.7, 53.3, 21.7, 15.7; IR
(KBr): 3270, 2927, 2793, 1642, 1454, 1261, 809
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI) <italic>m/z</italic>:
382[M&#x02009;+&#x02009;H]<sup>+</sup>; Anal. Calcd. for
C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>S: C, 66.12; H, 6.08; N, 11.01;
found C, 66.23; H, 6.26; N, 10.93.</p></sec><sec id="s0013"><label>2.1.10.</label><title>1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-nicotinoylpiperazin-1-yl)ethan-1-one
(15)</title><p>Yellow solid; yield 39%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 216.2&#x02013;216.8&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.70 (br s, NH),
8.65&#x02013;8.61 (m, 2H), 7.87&#x02013;7.82 (m, 2H), 7.50&#x02013;7.45 (m, 1H), 7.15 (s, 1H), 6.95 (br d, 1H),
3.68 (br s, 4H), 3.37 (br s, 2H), 2.67 (s, 3H), 2.56 (br s, 4H), 2.37 (s, 3H);
<sup>13</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 192.6, 167.2,
151.0, 148.1, 144.7, 135.7, 135.4, 132.3, 131.5, 125.1, 124.1, 123.5, 121.2, 116.2,
111.6, 66.7, 53.4, 52.9, 21.7, 15.7; IR (KBr): 3414, 3213, 2828, 1621, 1454, 1267, 1301,
817 <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI) <italic>m/z</italic>: 377
[M&#x02009;+&#x02009;H]<sup>+</sup>; Anal. Calcd. for
C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>: C, 70.19; H, 6.43; N, 14.88;
found C, 70.21; H, 6.44; N, 14.73.</p></sec><sec id="s0014"><label>2.1.11.</label><title>1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(2-methylbenzoyl)piperazin-1-yl)ethan-1-one
(16)</title><p>Yellow solid; yield 41%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 200.5&#x02013;201.6&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.70 (br s, NH),
7.85 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.31&#x02013;7.27 (m, 3H), 7.26&#x02013;7.24 (m, 2H), 7.15
(d, 1H), 3.69 (br s, 2H), 3.34 (br s, 2H), 3.15 (br s, 2H), 2.67 (s, 3H), 2.51 (br s,
4H), 2.44 (s, 3H), 2.38 (s, 3H); <sup>13</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>)
<italic>&#x003b4;</italic> 192.6, 169.0, 144.7, 135.7, 134.2, 131.8, 131.5, 130.7, 129.2,
126.4, 126.2, 123.4, 121.2, 112.8, 66.8, 53.5, 53.0, 46.8, 41.4, 21.7, 19.2, 15.7; IR
(KBr): 3431, 3221, 2919, 2797, 1615, 1454, 1257, 748
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI) <italic>m/z</italic>: 390
[M&#x02009;+&#x02009;H]<sup>+</sup>. Anal. Calcd. for
C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub>: C, 74.01; H, 6.99; N, 10.79;
found C, 74.01; H, 7.01; N, 10.63.</p></sec><sec id="s0015"><label>2.1.12.</label><title>1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(3-methoxybenzoyl)piperazin-1-yl)ethan-1-one
(17)</title><p>Yellow solid; yield 32%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 209.8&#x02013;210.4&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.71 (br s, NH),
7.85 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.34 (t, 1H), 7.15 (br s, 1H), 7.02&#x02013;6.92 (m,
4H), 3.78 (s, 3H), 3.68 (br s, 3H), 3.35 (br s, 3H), 2.67 (br s, 7H), 2.38 (s, 3H);
<sup>13</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 192.7, 169.1,
159.7, 144.7, 137.9, 135.7, 131.5, 130.2, 125.1, 123.4, 121.2, 119.4, 115.7, 112.7,
111.6, 66.8, 55.8, 53.3, 53.11, 47.4, 21.7, 15.7; IR (KBr): 3131, 3049, 2944, 1651,
1455, 1292, 1130, 968 <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI)
<italic>m/z</italic>: 406 [M&#x02009;+&#x02009;H]<sup>+</sup>. Anal. Calcd. for
C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub>: C, 71.09; H, 6.71; N, 10.36;
found C, 70.85; H, 6.45; N, 10.76.</p></sec><sec id="s0016"><label>2.1.13.</label><title>2-(4-(3,4-Difluorobenzoyl)piperazin-1-yl)-1-(2,6-dimethyl-1H-indol-3-yl)ethan-1-one
(18)</title><p>Yellow solid; yield 27%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 233.8&#x02013;235.0&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.71 (br s, NH),
7.85 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.56&#x02013;7.47 (m, 2H), 7.28 (br s, 1H), 7.15 (s,
1H), 6.96 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 3.68 (br s, 2H), 3.33 (br s, 2H), 2.67
(s, 3H), 2.51 (br s, 6H), 2.38 (s, 3H); MS (ESI) <italic>m/z</italic>: 412
[M&#x02009;+&#x02009;H]<sup>+</sup>; IR (KBr): 3252, 2919, 2795, 1618, 1469, 1286, 1046, 980
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI) 412 [M&#x02009;+&#x02009;H]<sup>+</sup>.
Anal. Calcd. for C<sub>23</sub>H<sub>23</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>: C,
67.14; H, 5.63; N, 10.21; found C, 67.43; H, 5.79; N, 10.59.</p></sec><sec id="s0017"><label>2.1.14.</label><title>2-(4-(3-Chlorobenzoyl)piperazin-1-yl)-1-(2,6-dimethyl-1H-indol-3-yl)ethan-1-one
(19)</title><p>Yellow solid; yield 32%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 222.3&#x02013;223.5&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 9.42 (br s, NH), 7.71
(d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.40&#x02013;7.25 (m, 4H), 7.04 (d,
<italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 2H), 3.85 (br s, 4H), 3.47 (br s, 2H), 2.80 (br s, 1H),
2.68 (br s, 6H), 2.40 (s, 3H); <sup>13</sup>C NMR (75&#x02009;MHz CDCl<sub>3</sub>,)
<italic>&#x003b4;</italic> 192.5, 169.0, 144.7, 137.5, 135.3, 134.7, 132.3, 130.0, 127.3,
125.2, 124.0, 123.7, 120.6, 112.8, 111.4, 67.0, 53.7, 53.7, 29.6, 21.5, 15.7; IR (KBr):
3264, 2916, 2795, 1646, 1454, 1256, 978, 809
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02013;1</sup>; MS (ESI) <italic>m/z</italic>: 410
[M&#x02009;+&#x02009;H]<sup>+</sup>. Anal. Calcd. for
C<sub>23</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub>: C, 67.39; H, 5.90; N, 10.25;
found C, 67.38; H, 5.90; N, 10.24.</p></sec><sec id="s0018"><label>2.1.15.</label><title>1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(4-methylbenzoyl)piperazin-1-yl)ethan-1-one
(20)</title><p>Yellow solid; yield 48%; column eluants: EtOAc, EtOAc/MeOH 9:1; m.p.: 230.9&#x02013;231.2&#x02009;&#x000b0;C;
<sup>1</sup>H NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic> 11.71 (br s, NH),
7.86&#x02013;7.82 (m, 1H), 7.31&#x02013;7.23 (m, 4H), 7.15 (s, 1H), 6.96 (d,
<italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 3.69 (br s, 2H), 3.35 (br s, 4H), 2.67 (s, 3H), 2.51.
IR (KBr): 3228, 2915, 2792, 1607, 1454, 1260, 979
<italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI) <italic>m/z</italic>: 390
[M&#x02009;+&#x02009;H]<sup>+</sup>; Anal. Calcd. for
C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub>: C, 74.01; H, 6.99; N, 10.79;
found C, 74.12; H, 7.02; N, 10.79.</p></sec><sec id="s0019"><label>2.1.16.</label><title>2-(4-(Cyclopentanecarbonyl)piperazin-1-yl)-1-(2,6-dimethyl-1H-indol-3-yl)ethan-1-one
(21)</title><p>Brown oil; yield 61%; column eluants: EtOAc, EtOAc/MeOH 9:1; <sup>1</sup>H NMR
(300&#x02009;MHz, CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 9.00 (br s, NH), 7.73 (d,
<italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.26 (br d, 1H), 7.12 (s, 1H), 7.05 (d,
<italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 3.83 (s, 2H), 3.75 (br s, 2H), 3.63 (br s, 2H),
2.80&#x02013;2.71 (m, 7H), 2.45 (s, 3H), 1.92&#x02013;1.46 (m, 7H); IR (KBr): 3253, 2944, 2862, 1650,
1620, 1455, 1234, 957 <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI)
<italic>m/z</italic>: 368 [M&#x02009;+&#x02009;H]<sup>+</sup>; Anal. Calcd. for
C<sub>22</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>: C, 71.90; H, 7.95; N, 11.43;
found C, 72.23; H, 8.31; N, 11.32.</p></sec><sec id="s0020"><label>2.1.17.</label><title>1-(4-(2-(2,6-Dimethyl-1H-indol-3-yl)-2-oxoethyl)piperazin-1-yl)heptan-1-one
(22)</title><p>Brown oil; yield 76%; column eluants: EtOAc, EtOAc/MeOH 9:1; <sup>1</sup>H NMR
(300&#x02009;MHz, CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 10.25 (br s, NH), 7.68 (d,
<italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.08 (s, 1H), 7.00 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz,
1H), 3.83 (s, 2H), 3.73 (br s, 2H), 3.56 (br s, 2H), 2.77&#x02013;2.71 (m, 3H), 2.62 (s, 3H),
2.38 (s, 3H), 2.32&#x02013;2.27 (m, 5H), 1.59&#x02013;1.54 (m, 2H), 1.26 (br s, 4H), 0.85 (br t, 3H);
<sup>13</sup>C NMR (75&#x02009;MHz, CDCl<sub>3</sub>) <italic>&#x003b4;</italic> 191.7, 172.4, 145.4,
135.5, 132.1, 124.0, 123.6, 120.4, 112.4, 111.6, 66.2, 53.3, 53.1, 45.3, 41.2, 34.5,
31.6, 28.9, 25.0, 22.5, 21.5, 15.6, 14.1; IR (KBr): 2927, 2857, 1731, 1645, 1455, 1434,
1234, 668 <italic>&#x003bd;</italic><sub>max</sub>/cm<sup>&#x02212;1</sup>; MS (ESI)
<italic>m/z</italic>: 384 [M&#x02009;+&#x02009;H]<sup>+</sup>; Anal. Calcd. for
C<sub>23</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub>: C, 72.03; H, 8.67; N, 10.96;
found C, 72.03; H, 8.73; N, 11.21.</p></sec></sec><sec id="s0021"><label>2.2.</label><title>Cell lines</title><p>Madin-Darby canine kidney (MDCK) cells stably expressing One Strep Tag DGK&#x003b1; (OST-DGK&#x003b1;)
were prepared by infecting MDCK cells with a vector expressing an inducible OST tagged
DGK&#x003b1; constructs<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>. MDCK cells
infected with empty vector were used as controls. MDCK cells were cultured in MEM (minimal
essential medium) with 5% FBS (foetal bovine serum) and 1% antibiotic&#x02013;antimycotic
solution. Routinely, cells were splitted every 3&#x02013;4&#x000a0;days with trypsin&#x02013;EDTA 0.25% in
standard 100&#x02009;mm dishes.</p><p>Human embryonic kidney 293T cells (10&#x02009;cm<sup>2</sup> plates) were cultured in RPMI with
10% FBS and 1% penicillin/streptomycin and cultures were maintained by splitting them for
every 2&#x02013;3&#x000a0;days using trypsin&#x02013;EDTA 0.25%.</p><p>Michigan Cancer Foundation 7 (MCF7) cells were cultured in DMEM with 10% FBS + 1%
penicillin/streptomycin and cultures were maintained by splitting them for every 2&#x02013;3&#x000a0;days
using trypsin&#x02013;EDTA 0.25%.</p></sec><sec id="s0022"><label>2.3.</label><title>Primary cells</title><p>PBL were isolated from healthy anonymous human donors by Ficoll-Paque PLUS (GE
Healthcare, Chicago, IL) density gradient centrifugation, washed, and resuspended at
2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cell/mL in RPMI-GlutaMAX containing 10% heat inactivated FCS, 2&#x02009;mM
glutamine, and 100&#x02009;U/mL of penicillin and streptomycin. T cells were activated with
1&#x02009;&#x000b5;g/mL anti-CD3 (UCHT1) and anti-CD28 (clone CD28.2) antibodies. After three&#x000a0;days,
activated T cells were washed and cultured in medium additionated of 100&#x02009;IU/mL rhIL-2
(Peprotech, Rocky Hill, NJ) at 1.2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/mL for &#x02265;7&#x000a0;days by changing media
for every 2&#x02013;3&#x000a0;days.</p><p>Human monocytes were isolated from healthy anonymous human buffy coats (provided by the
Transfusion Service of Ospedale Maggiore della Carit&#x000e0;, Novara, Italy) by the standard
technique of dextran sedimentation and Histopaque (density = 1.077&#x02009;g&#x000a0;cm<sup>3</sup>,
Sigma-Aldrich, Milano, Italy) gradient centrifugation (400&#x000d7;<italic>g</italic>, 30&#x02009;min,
room temperature) and recovered by fine suction at the interface, as described
previously<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>. Purified monocytes
populations were obtained by adhesion (90&#x02009;min, 37&#x02009;&#x000b0;C, 5% CO<sub>2</sub>) in serum-free
RPMI 1640 medium (Sigma-Aldrich, Milano, Italy) supplemented with 2&#x02009;mM glutamine and
antibiotics. Cell viability (trypan blue dye exclusion) was usually &#x0003e;98%.</p></sec><sec id="s0023"><label>2.4.</label><title>Preparation of DGK&#x003b1; enriched homogenates</title><p>Large cultures of MDCK cells for enzyme preparation were done by plating
5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells in 245&#x02009;mm<sup>2</sup> dishes. Once they reached nearly 70%
confluence, cells were treated with doxycycline (1&#x000a0;&#x000b5;g/mL, two&#x000a0;days). After two&#x000a0;days of
treatment, each plate was washed in cold PBS and cells homogenised in 5&#x02009;mL of homogenate
buffer (25&#x02009;mM Hepes (pH 8), 20% glycerol, 135&#x02009;mM NaCl, 5&#x02009;mM ethylenediaminetetraacetic
acid (EDTA), 1&#x02009;mM ethylene glycol-bis(beta-aminoethyl ether)-N,N,N&#x02032;,N&#x02032;-tetraacetic acid
(EGTA), 1&#x02009;mM sodium orthovanadate, and protease inhibitor cocktail) for each dish. Cells
were collected with a rubber scraper, homogenised by passing them through a 29&#x02009;G-needle
syringe 20 times and stored in aliquots at &#x02013;80&#x02009;&#x000b0;C. Presence of OST-DGK&#x003b1; was confirmed by
western blotting and enzyme assay, transduced DGK&#x003b1; has an activity &#x0003e;100 folds the
endogenous DGK.</p></sec><sec id="s0024"><label>2.5.</label><title>Preparation of DGK&#x003b6; and DGK&#x003b8; enriched homogenates</title><p>293T cells were transiently transfected with indicated DGK isoform plasmid DNA using
Lipofectamine 3000, Invitrogen (Carlsbad, CA). Forty eight hours after transfection, cells
were harvested and homogenised with a 29&#x02009;G-needle using 500&#x02009;&#x000b5;L of homogenate buffer for
each dish and immediately stored in aliquots at &#x02013;80&#x02009;&#x000b0;C. Cells transfected with empty
vector were used as controls, overexpressed DGK has an activity &#x0003e;50 folds the
endogenous.</p></sec><sec id="s0025"><label>2.6.</label><title>DGK assay</title><p>Essentionally, the same procedure was followed as reported previously in Velnati
et&#x000a0;al.<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref> In brief, DGK activity was
assayed by measuring initial velocities (5&#x02009;min at 27&#x02009;&#x000b0;C) in presence of saturating
substrate concentrations. Reaction conditions: 0.9&#x000a0;&#x000b5;g/&#x000b5;L 1,2-dioleoyl-sn-glycerol, 5&#x02009;mM
ATP, 0.01&#x000a0;&#x000b5;Ci/&#x000b5;L [&#x003b3;<sup>32</sup>P]-ATP, 1&#x02009;mM sodium orthovanadate, 10&#x02009;mM MgCl<sub>2</sub>,
1.2&#x02009;mM EGTA in 7.5&#x02009;mM Hepes pH 8<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>.
Reaction mixture is assembled mixing enzyme (24.5&#x000a0;&#x000b5;L of homogenate), 100&#x000d7; inhibitor or
DMSO (0.5&#x000a0;&#x000b5;L), 5&#x000d7; ATP solution (10&#x000a0;&#x000b5;L of 25&#x02009;mM ATP, 0.05&#x000a0;&#x000b5;Ci/&#x000b5;L [&#x003b3;<sup>32</sup>P]-ATP
(Perkin-Elmer, Milan, Italy), 5&#x02009;mM sodium orthovanadate, 50&#x02009;mM MgCl<sub>2</sub>), and 3.3&#x000d7;
DAG solution (15&#x000a0;&#x000b5;L of 3&#x000a0;&#x000b5;g/&#x000b5;L 1,2-dioleoyl-sn-glycerol resuspended by sonication in 4&#x02009;mM
EGTA in 25&#x02009;mM Hepes pH 8). The reaction was stopped after 5&#x02009;min by adding 200&#x000a0;&#x000b5;L of
freshly prepared 1&#x000a0;M HCl and lipid was extracted by adding 200&#x000a0;&#x000b5;L of
CH<sub>3</sub>OH:CHCl<sub>3</sub> 1:1 solution and vortexing for 1&#x02009;min. The two phases
were separated by centrifugation (12,000 RCF for 2&#x02009;min). Twenty-five microlitres of the
lower organic phase was spotted in small drops on silica TLC plates. TLC was run 10&#x02009;cm and
dried before radioactive signals were detected by GS-250 molecular imager and was
quantified by quantity one (Bio-Rad, Hercules, CA) software assuring the absence of
saturated spots.</p><p>Percentage residual activity was calculated as follows: (OST-DGK&#x003b1; homogenate with
inhibitor&#x000a0;&#x02013;&#x000a0;vector homogenate)/(OST-DGK&#x003b1; homogenate with DMSO&#x000a0;&#x02013;&#x000a0;vector
homogenate)&#x000d7;100.</p></sec><sec id="s0026"><label>2.7.</label><title>Superoxide anion (O<sup>2&#x02212;</sup>) production</title><p>All the experiments were performed in triplicate using cells isolated from each single
donor.</p><p>Monocytes (250,000 cells/well) were treated for 1&#x02009;h with the indicated drugs (10&#x02009;&#x000b5;M) with
or without serotonin (1&#x02009;&#x000b5;M). Then, cells were stimulated with phorbol 12-myristate
13-acetate (PMA; Sigma-Aldrich, Milano, Italy) 1&#x02009;&#x000b5;M for 30&#x02009;min. PMA is a well-known
stimulus that induces a strong and significant respiratory burst via PKC activation<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>. Superoxide anion production was then
evaluated by the superoxide dismutase (SOD)-sensitive cytochrome C (CytC) reduction assay
and expressed as nmoles CytC reduced/10<sup>6</sup> cells/30&#x02009;min, using an extinction
coefficient of 21.1&#x02009;mM. To avoid interference with spectrophotometrical recordings, cells
were incubated with RPMI 1640 without phenol red, antibiotics, and FBS.</p></sec><sec id="s0027"><label>2.8.</label><title>RICD assay in SAP silenced T cells</title><p>Activated human PBLs were transfected with 200&#x02009;pmol of siRNA oligonucleotides specific
for the target protein (Stealth Select siRNA; Life Technologies, Carlsbad, CA) or a
non-specific control oligo (Life Technologies, Carlsbad, CA). Transient transfections were
performed using Amaxa nucleofector kits for human T cells (Lonza, Basel, Switzerland) and
the Amaxa Nucleofector II or 4D systems (programmes T-20 or EI-115). Cells were cultured
in IL-2 (100&#x02009;IU/mL) for four&#x000a0;days to allow target gene knockdown. Knockdown efficiency was
periodically evaluated by Western blotting.</p><p>Non-specific Stealth RNAi Negative Control Duplexes (12935-300, Life Technologies,
Carlsbad, CA) were used as a negative control.</p><p>siRNA SAP: sense strand UGUACUGCCUAUGUGUGCUGUAUCA, antisense strand
UGAUACAGCAGACAUAGGCAGUACA.</p><p>To test restimulation induced cell death, activated T cells (10<sup>5</sup> cells/well)
were plated in triplicate in 96-well round-bottom plate and treated with anti-CD3 (clone
OKT3) (10&#x02009;ng/mL) in RPMI-GlutaMAX supplemented with 100&#x02009;IU/mL rhIL-2 for 24&#x02009;h. In these
assays, inhibitors (10&#x02009;&#x000b5;M) were added 30&#x02009;min before the restimulation with OKT3. 24&#x02009;h
after treatment, cells were stained with 20&#x02009;ng/mL propidium iodide and collected for a
constant time of 30&#x02009;s per sample on Attune Nxt Flow Cytometer (Thermo Fisher Scientific,
Waltham, MA). Cell death is expressed as % cell loss and calculated as: <disp-formula id="M0001"><alternatives><graphic xlink:href="IENZ_A_1684911_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d1e1958"><mml:mrow><mml:mi>%</mml:mi><mml:mi>&#x000a0;</mml:mi><mml:mtext>cell</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>loss</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>number</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>of</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>viable</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>cells</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>in</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>sample</mml:mtext></mml:mrow><mml:mrow><mml:mtext>number</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>of</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>viable</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>cells</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>in</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>control</mml:mtext></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></p><p>Results were expressed as mean&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM). We always compared
controls and SAP silenced lymphocytes from the same donors as there is a large individual
variability in RICD sensitivity.</p></sec><sec id="s0028"><label>2.9.</label><title>Migration assays</title><p>Cell migration assays were performed using the Culture-Insert 2 well in &#x000b5;-Dish (ibidi
GmbH, Martinsried, Germany).</p><p>Briefly, 25,000 MCF7 cells were plated in each well and cultured for 24&#x02009;h. The day after,
the culture insert was removed and the cells were washed with PBS before treating them
with respective DGK&#x003b1; inhibitors (10&#x02009;&#x000b5;M) or DMSO for 15&#x02009;h in complete medium (DMEM 10% FBS
+ 1% penicillin/streptomycin), while medium without FBS was used as a negative control for
migration.</p><p>Phase-contrast pictures were taken immediately after treatment (0&#x02009;h) and after 15&#x02009;h under
5&#x000d7; magnification.</p><p>Finally, wound areas were determined using ImageJ software (NIH, , Bethesda, MD). Wound
reduction was calculated by using the following formula: (wound area at 15&#x02009;h/wound at
0&#x02009;h)&#x000d7;100, the values obtained were expressed as the percentage of wound area compared to
the initial area.</p></sec><sec id="s0029"><label>2.10.</label><title>Quantification and statistical analysis</title><p>Data for the screen on OST-DGK&#x003b1; homogenates are the mean of duplicates. The compounds
showing inhibitory activity in this assay were tested &#x0003e;4 times and the mean&#x02009;&#x000b1;&#x02009;SEM is
reported.</p><p>To calculate IC<sub>50</sub> values of active inhibitors, the inhibitor activity was
measured at least three times at 0.1, 1.0, 10.0, and 100.0&#x000a0;&#x000b5;M concentration. Data were
analysed using [inhibitor] vs. normalised response parameters with least square [ordinary]
curve fitting method in GraphPad PRISM 8.0 software (GraphPad Software, La Jolla, CA)
mentioning 95% confidence interval and IC<sub>50</sub> values always greater than 0.0.
Graph shows the mean&#x02009;&#x000b1;&#x02009;SEM of inhibitor activity at the indicated concentration. In all
the experiments, the data were normalised with the controls.</p><p>Evaluation of <italic>in&#x000a0;vitro</italic> assays across multiple treatments (RICD),
SOD-sensitive CytC reduction assay, migration assays were analysed by using one-way ANOVA
with multiple comparisons correction using GraphPad PRISM 8.0 software (GraphPad Software,
La Jolla, CA). Error bars are described in figure legends as&#x02009;&#x000b1;&#x02009;SEM or&#x02009;&#x000b1;&#x02009;SD where
appropriate. A single, double, triple and four asterisk denotes significance of a
<italic>p</italic> value &#x02264;0.05, &#x02264;0.01, &#x02264;0.001, and &#x02264;0.0001 respectively in all
experiments.</p></sec><sec id="s0030"><label>2.11.</label><title>Pharmacophoric model</title><p>A representative 3D structure of each compound was generated using OMEGA2 software<xref rid="CIT0034" ref-type="bibr"><sup>34&#x02013;36</sup></xref>. The generated
file was used to generate a pharmacophore model with the Pharmagist web server (<ext-link ext-link-type="uri" xlink:href="http://bioinfo3d.cs.tau.ac.il/PharmaGist/">bioinfo3d.cs.tau.ac.il/PharmaGist/</ext-link>)<xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref>.</p></sec></sec><sec id="s0031"><label>3.</label><title>Results</title><sec id="s0032"><label>3.1.</label><title>Chemistry</title><p>At the beginning, we purchased 14 analogues of Amb639752 by vendors (<xref ref-type="fig" rid="F0003">Figure 3</xref>), while one analogue (<bold>2</bold>), being not
commercially available, was synthesised (see <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1684911">Supplementary
material</ext-link>). All the compounds were evaluated for their inhibitory activity on
DGK&#x003b1; at a concentration of 100&#x02009;&#x000b5;M (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>First set of compounds tested for their inhibitory activity on DGK&#x003b1;.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0003_B"/></fig><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Inhibitory activity on DGK&#x003b1; (I).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Compound</th><th align="center">Residue activity at
100&#x000a0;&#x000b5;M</th></tr></thead><tbody valign="top"><tr><td align="left">R59022</td><td align="char" char=".">27</td></tr><tr><td align="left">R59949</td><td align="char" char=".">28</td></tr><tr><td align="left">Amb639752</td><td align="char" char=".">4</td></tr><tr><td align="left">Amb758897</td><td align="char" char=".">67</td></tr><tr><td align="left">Amb37496</td><td align="char" char=".">114</td></tr><tr><td align="left">Amb626577</td><td align="char" char=".">127</td></tr><tr><td align="left">Amb1926062</td><td align="char" char=".">88</td></tr><tr><td align="left">Amb94966</td><td align="char" char=".">196</td></tr><tr><td align="left">Amb730692</td><td align="char" char=".">45</td></tr><tr><td align="left">Amb98433</td><td align="char" char=".">81</td></tr><tr><td align="left">Amb18718</td><td align="char" char=".">135</td></tr><tr><td align="left">Amb726054</td><td align="char" char=".">126</td></tr><tr><td align="left">Amb731111</td><td align="char" char=".">130</td></tr><tr><td align="left">Amb22018852</td><td align="char" char=".">160</td></tr><tr><td align="left">Amb687392</td><td align="char" char=".">115</td></tr><tr><td align="left">Amb758592</td><td align="char" char=".">150</td></tr><tr><td align="left">Amb629700</td><td align="char" char=".">101</td></tr><tr><td align="left"><bold>2</bold></td><td align="char" char=".">135</td></tr></tbody></table></table-wrap><p>Each inhibitor was tested in duplicate at least once, and DGK&#x003b1; activity was expressed as
percentage of residual DGK&#x003b1; activity compared to DMSO control in the same assay. Assay
uses OST-DGK&#x003b1; overexpressing cell lysates in presence of saturating exogenous DAG and ATP.
We considered R59022 (commercially available) and the lead compound Amb63975230 as our
reference molecules. As expected, our reference inhibitors R59022 and Amb639752 featured
73% and 96% inhibition respectively, confirming the quality of data obtained.</p><p>This first screening showed us how Amb639752 exhibits a rigid structure activity
relationship. Indeed, both the methyl groups on the 2,6 position of indole are mandatory,
the NH indole cannot be alkylated as well as ramifications on the alkyl chain are
detrimental. We then focussed our attention on furan ring knowing its intrinsic toxicity
via metabolic activation<xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>.
Unfortunately, there were no analogues available by vendors. Our first goal was to replace
the furan moiety with the phenyl ring, investigating two different synthetic pathways.</p><p>In the first one, the commercially available 2,6-dimethyl-1<italic>H</italic>-indole
<bold>3</bold> was acylated with 2-chloroacetyl chloride <bold>4</bold>, in the presence
of DBU in dichloroethane<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref> to give
the derivative <bold>5</bold> 90% yield. Then, the acylated compound <bold>5</bold> was
reacted with <italic>N</italic>-Boc piperazine in the presence of potassium carbonate and
potassium iodide to afford the piperazinic derivative <bold>6</bold> in 63% yield. Boc
deprotection with trifluoroacetic acid, followed by coupling with benzoic acid using the
condensing agent EDCI afforded the final compound <bold>8</bold> (<xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>).</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>The first synthetic route for the compound <bold>8</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_SCH0001_B"/></fig><p>In the second synthetic strategy, we initially coupled the benzoic acid with
<italic>N</italic>-Boc piperazine in the presence of EDCI to give piperazinic derivative
<bold>9</bold> in 49% yield. Boc deprotection gave in quantitative yield the compound
<bold>10</bold>. Due to its high aqueous solubility, solvent was evaporated and the
crude as trifluoroacetate salt was directly used for the next step, where it was reacted
with the acylated indole <bold>5</bold> to give the final compound <bold>8</bold> in 25%
yield (<xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>) (see <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1684911">Supplementary material</ext-link> for full synthetic details).</p><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>The second synthetic route for the compound <bold>8</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_SCH0002_B"/></fig><p>Overall yield calculation was 11% for both strategies, but with the first route it was
possible to use a common synthetic intermediate <bold>7</bold> which can be coupled with
different carboxylic acids. Furthermore, the second route requires more purification
steps. For this reason, we applied the first route and coupled the advanced intermediate
<bold>7</bold> with 12 different carboxylic acids (<xref ref-type="fig" rid="F0004">Figure 4</xref>) to afford compounds <bold>11</bold>&#x02013;<bold>22</bold> (<xref ref-type="fig" rid="F0005">Figure 5</xref>).</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Carboxylic acids used.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0004_B"/></fig><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Putative DGK&#x003b1; inhibitors synthesised. In brackets the yield of the coupling reaction
with the common intermediate <bold>7</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0005_B"/></fig><p>All those molecules were dissolved in DMSO and tested at a concentration of 100&#x02009;&#x000b5;M for
the ability to inhibit DGK&#x003b1; using equal amounts of DMSO as control. We identified eight
compounds capable of reducing OST-DGK&#x003b1; activity similar or superior to R59022 (<xref rid="t0002" ref-type="table">Table 2</xref>).</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Inhibitory activity on DGK&#x003b1; (II).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Compound</th><th align="center">Residue activity at
100&#x000a0;&#x000b5;M</th><th align="center">IC<sub>50</sub> (&#x000b5;M)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>8</bold></td><td align="char" char=".">5</td><td align="char" char=".">3.2</td></tr><tr><td align="left"><bold>11</bold></td><td align="char" char=".">6</td><td align="char" char=".">1.6</td></tr><tr><td align="left"><bold>12</bold></td><td align="char" char=".">6</td><td align="char" char=".">3.6</td></tr><tr><td align="left"><bold>13</bold></td><td align="char" char=".">14</td><td align="char" char=".">6.9</td></tr><tr><td align="left"><bold>14</bold></td><td align="char" char=".">6</td><td align="char" char=".">3.0</td></tr><tr><td align="left"><bold>15</bold></td><td align="char" char=".">89</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>16</bold></td><td align="char" char=".">27</td><td align="char" char=".">32.8</td></tr><tr><td align="left"><bold>17</bold></td><td align="char" char=".">41</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>18</bold></td><td align="char" char=".">47</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>19</bold></td><td align="char" char=".">26</td><td align="char" char=".">49.7</td></tr><tr><td align="left"><bold>20</bold></td><td align="char" char=".">3</td><td align="char" char=".">1.8</td></tr><tr><td align="left"><bold>21</bold></td><td align="char" char=".">39</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>22</bold></td><td align="char" char=".">48</td><td align="center">&#x02013;</td></tr></tbody></table></table-wrap></sec><sec id="s0033"><label>3.2.</label><title>Potency and isoform specificity of active molecules</title><p>To measure the inhibitor potency, we determined the IC<sub>50</sub> values for the
compounds that resulted active when tested at 100&#x02009;&#x000b5;M by measuring the residual OST-DGK&#x003b1;
activity over a dose range of inhibitor concentrations (0.1&#x02009;&#x000b5;M, 1.0&#x02009;&#x000b5;M, 10.0&#x02009;&#x000b5;M, and
100.0&#x02009;&#x000b5;M).</p><p>For R59022 and Amb639752, we measured IC<sub>50</sub> values of 15.2&#x02009;&#x000b1;&#x02009;5.8&#x02009;&#x000b5;M and
6.9&#x02009;&#x000b1;&#x02009;3.0&#x02009;&#x000b5;M respectively which were comparable to previous reports using similar assay
conditions<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. Considering those two
as reference/template compounds, we measured the IC<sub>50</sub> values of <bold>8</bold>,
<bold>11</bold>, <bold>12</bold>, <bold>13</bold>, <bold>14</bold>, <bold>16</bold>,
<bold>19</bold>, and <bold>20</bold> as 3.2&#x02009;&#x000b1;&#x02009;1.0, 1.6&#x02009;&#x000b1;&#x02009;0.4, 3.6&#x02009;&#x000b1;&#x02009;1.2, 6.9&#x02009;&#x000b1;&#x02009;2.3,
3.0&#x02009;&#x000b1;&#x02009;1.0, 32.8&#x02009;&#x000b1;&#x02009;11.5, 49.7&#x02009;&#x000b1;&#x02009;31.7, and 1.8&#x02009;&#x000b1;&#x02009;0.4&#x02009;&#x000b5;M, respectively, signifying that their
activity is equal or superior to the template compounds (<xref ref-type="fig" rid="F0006">Figure 6)</xref>.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Dose&#x02013;response curves for novel DGK&#x003b1; inhibitors. Dose&#x02013;response of the most active
compounds along with their IC<sub>50</sub> values. Data from at least three
independent experiments performed in triplicate.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0006_B"/></fig><p>Due to their higher IC<sub>50</sub> values, we thus decided to exclude <bold>16</bold>
and <bold>19</bold> for further experiments. In summary, we recognised six compounds with
equal or superior inhibitory activity compared to commercially available DGK&#x003b1;
inhibitors.</p><p>To check the isoform specificity of those active molecules, we tested them, along with
Amb639752, for their ability to inhibit DGK&#x003b1;, DGK&#x003b6; (the other major DGK isoform expressed
in lymphocytes), and the more distantly related and widely expressed DGK&#x003b8;. At the highest
concentration of 100&#x000a0;&#x000b5;M, all those molecules resulted in highly specific against DGK&#x003b1; as
like their parent molecule, Amb639752 by completely inhibit DGK&#x003b1; whereas they do not have
significant effects on DGK&#x003b6; and DGK&#x003b8; apart from <bold>20</bold> which, at the contrary,
acts as an activator of DGK&#x003b8; (<xref ref-type="fig" rid="F0007">Figure 7)</xref>.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Isoform specificity of novel DGK&#x003b1; inhibitors. 293T cells were transfected with
different DGK isoforms (A &#x02013; DGK&#x003b1;, B &#x02013; DGK&#x003b6;, C &#x02013; DGK&#x003b8;, respectively) or empty vectors
and homogenised. All the molecules were tested at 100&#x02009;&#x003bc;M for their capacity to inhibit
the DGK activity of the different isoform homogenates. Data are means&#x02009;&#x000b1;&#x02009;SEM of at
least three independent experiments performed in triplicate.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0007_B"/></fig></sec><sec id="s0034"><label>3.3.</label><title>Activity of compounds on serotonin receptors</title><p>R59022, R59949, and ritanserin feature a dual activity as DGK&#x003b1; inhibitors and serotonin
receptor antagonists<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. Conversely,
Amb639752 was reported as a selective DGK&#x003b1; inhibitor which has no effects on serotonin
activity<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. Thus, we investigated
whether the active molecules identified affect serotonin signalling.</p><p>To this purpose, we measured the effect of serotonin on PMA-induced oxidative burst in
human monocytes. As previously shown, 1&#x02009;&#x000b5;M serotonin reverses the oxidative burst to
control values<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>. Known serotonin
receptor antagonists ritanserin and ketanserin (10&#x02009;&#x000b5;M) impaired serotonin action, while
pure DGK&#x003b1; inhibitors such as Amb639752 had no effect (<xref ref-type="fig" rid="F0008">Figure 8)</xref>. These data indicate that this assay is sensitive to perturbations in
serotonin signalling independently of activity against DGK&#x003b1;. Interestingly, as like
Amb639752, all the newly synthesised active molecules did not affect serotonin action
(<xref ref-type="fig" rid="F0008">Figure 8</xref>), indicating that all those molecules
are not serotonin receptor antagonists.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Novel DGK&#x003b1; inhibitors do not affect serotonin signalling. Human monocytes were
pre-incubated for 1&#x02009;h with the indicated drugs in absence or presence of serotonin and
then stimulated with PMA 1&#x000a0;&#x000b5;M for 30&#x02009;min (&#x025a0; control unstimulated cells,
<inline-graphic xlink:href="IENZ_A_1684911_ILG0001_B.jpg" content-type="black-white"/> PMA stimulated cells, &#x025a0; PMA and serotonin stimulated cells). Results are expressed
as n&#x000a0;moles of reduced cytochrome C/10<sup>6</sup> cells. Data are means&#x02009;&#x000b1;&#x02009;SEM of 10
independent experiments performed in triplicate.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0008_B"/></fig></sec><sec id="s0035"><label>3.4.</label><title>DGK&#x003b1; inhibitors restore RICD in SAP deficient T cells</title><p>Ruffo et&#x000a0;al. demonstrated that the defective RICD observed in T cells from XLP-1 patients
was rescued by silencing DGK&#x003b1; expression or by pre-treatment with DGK&#x003b1; inhibitors R59949
or R59022<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. Interestingly, R59022
also showed beneficial effects in an <italic>in&#x000a0;vivo</italic> model of XLP-1, but due to
its poor pharmacological proprieties, its use in human patients results unlikely. We
therefore tested the effect all those active molecules along with Amb639752 on RICD
sensitivity of SAP-deficient T cells. As additional controls, we also included ritanserin
and ketanserin to evaluate the contribution of serotonin antagonism to the effects
observed.</p><p>To evaluate inhibitor efficacy in physiological context, we modelled XLP-1 by silencing
SAP in primary peripheral blood T lymphocytes (PBLs) and restimulating them with anti-CD3
antibody (OKT3 10&#x02009;ng/mL, 24&#x02009;h). We pre-treated the cells with the indicated inhibitors for
30&#x02009;min at a concentration of 10&#x02009;&#x000b5;M<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>.
In control siRNA-transfected cells, DGK&#x003b1; inhibitors poorly affect RICD, with Amb639752,
<bold>11</bold> and <bold>14</bold> slightly reducing it (<xref ref-type="fig" rid="F0009">Figure 9)</xref>. Conversely, DGK&#x003b1; inhibitors significantly rescued the
apoptotic defect of SAP-deficient T cells although not reaching control levels. At 10&#x02009;&#x000b5;M,
all the new molecules showed an efficacy comparable to Amb637952 and ritanserin used as
positive reference molecules. Conversely, the serotonin antagonist ketanserin is inactive,
excluding the involvement of serotonin receptors in rescuing the RICD in SAP-deficient T
cells (<xref ref-type="fig" rid="F0009">Figure 9)</xref>.</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>DGK&#x003b1; inhibitors partially restores apoptosis in SAP deficient lymphocytes.
Lymphocytes from normal subjects were transfected with control or SAP specific siRNA
(&#x025a0; control siRNA, &#x025a0; SAP siRNA). After 4&#x000a0;days, the cells were restimulated with CD3
agonist OKT3 (10&#x02009;ng/mL) in presence of respective inhibitor. Vehicle (DMSO) was used
as control. Twenty-four hours later, the % of cell loss was evaluated by PI staining.
Data are the mean&#x02009;&#x000b1;&#x02009;SEM of nine independent experiments performed in triplicate.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0009_B"/></fig><p>In summary, these data confirm that the newly identified DGK&#x003b1; inhibitors can rescue RICD
susceptibility in T cell models of XLP-1 suggesting a putative use for XLP-1 therapy.</p></sec><sec id="s0036"><label>3.5.</label><title>DGK&#x003b1; inhibitors reduce migration of the cancer cells (MCF7)</title><p>Previous studies conducted in our laboratory demonstrated that the inhibition of DGK
activity decreases chemotaxis, proliferation, migration, and invasion of many cancer cell
lines<xref rid="CIT0012" ref-type="bibr"><sup>12&#x02013;14</sup></xref>. To
evaluate if our newly synthetised DGK&#x003b1; inhibitors were effective in impairing cancer cell
migration, we measured serum induced wound healing in MCF7 breast cancer cells in presence
of 10&#x000a0;&#x000b5;M inhibitor. In presence of serum, none of the inhibitors is toxic for MCF7 cells
even after prolonged treatment (data not shown). After 15&#x02009;h of treatment, all the newly
synthesised active molecules equally reduced cell migration when compared to the vehicle
(DMSO) delaying wound closure (<xref ref-type="fig" rid="F0010">Figure 10)</xref>.</p><fig id="F0010" orientation="portrait" position="float"><label>Figure 10.</label><caption><p>Novel DGK&#x003b1; inhibitors slow tumour cell migration. MCF7 monolayer was wounded and
treated for 15&#x02009;h with serum in presence of our new DGK&#x003b1; inhibitors (10&#x02009;&#x003bc;M) or vehicle
(DMSO). Results are expressed as the percentage of wound area compared to the initial
area. Data are the mean&#x02009;&#x000b1;&#x02009;SEM of nine independent experiments.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1684911_F0010_B"/></fig><p>Besides being in good agreement with the notion that DGK&#x003b1; is required for cancer cells
migration, this observation indicates that our new DGK&#x003b1; inhibitors reduce cancer cell
motility, suggesting a potential utility in a metastasis setting.</p></sec><sec id="s0037"><label>3.6.</label><title>Generation of a pharmacophore hypothesis</title><p>From the data obtained, it is possible to identify some key pharmacophoric points crucial
for the biological activity of the Amb compounds on DGKs namely: (i) a basic nitrogen;
(ii) the methyl groups at the 2 and 6 position of the indole nucleus, and (iii) a
(hetero)aromatic ring. This information allows us to build a four-point pharmacophoric
model represented in <xref ref-type="fig" rid="F0011">Figure 11</xref> superimposed with
the minimised structure of compound <bold>11</bold>. Although, we are not able to evaluate
the importance of the two carbonyl groups, it represents the first attempts in order to
identify the minimum structural request to interact with DGK catalytic site considering
the molecular structure of the four most active inhibitors discovered to date (Amb639752,
ritanserin, R59022, and R59949). We feel that this model might be useful to identify novel
compounds active on DGK&#x003b1; through more targeted virtual screening campaigns, overcoming the
current scaffolds.</p><fig id="F0011" orientation="portrait" position="float"><label>Figure 11.</label><caption><p>Proposed pharmacophoric model.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1684911_F0011_C"/></fig></sec></sec><sec id="s0038"><label>4.</label><title>Discussion</title><p>As a key component of several signal transduction pathways, DGK&#x003b1; represent an emerging
pharmacological target. We have demonstrated the efficacy of DGK&#x003b1; inhibitors for XLP-1
treatment<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>, while others have
proposed them for cancer treatment<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>
and to remove immune-checkpoints promoting immune vigilance against cancer<xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref>. Commercially available DGK&#x003b1; inhibitors
are limited by poor specificity<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref>
and pharmacokinetic<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. The CU-3
molecule described by other features a noteworthy activity and specificity but its reactive
chemical structure make unlikely an <italic>in&#x000a0;vivo</italic> use<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>. With intent of developing molecules suitable for
therapeutic use we selected Amb639752 as a novel inhibitor with remarkable DGK&#x003b1; activity.
Amb639752 also features improved selectivity for DGK&#x003b1; as it does not affect serotonin
signalling<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. Despite numerous
efforts a structure of mammalian DGKs is still missing, thus we decided to explore the
structure&#x02013;activity relationship of this molecule to improve its activity and pave the way
for further developments. Our efforts allowed us to build a pharmacophoric model for DGK&#x003b1;
inhibitors characterised by three required features. We also characterised a set of novel
compounds with improved IC<sub>50</sub> in the low &#x000b5;M range and identified the most
profitable synthetic route for them. The mode of DGK&#x003b1; inhibition by those molecules is still
unknown apart for ritanserin, which binds at the same time the DGK&#x003b1; catalytic accessory
domain and the C1 domain putatively promoting a close inactive conformation<xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref>.</p><p>The second-generation inhibitors we described in this work maintain the specificity of
Amb639752 as they not affect DGK&#x003b6;, the predominant isoform of lymphocytes<xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref> and the broadly expressed DGK&#x003b8;<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>. Those DGK&#x003b1; inhibitors are active in a
lymphocyte based XLP-1 assay and in a cancer cell migration assay, holding the promise for a
potential therapeutic application. However, their efficacy is still to be determined in
<italic>in&#x000a0;vivo</italic> models of disease where some of the parental compounds showed
efficacy but poor pharmacokinetic<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM5976"><caption><title>Supplemental Material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="IENZ_A_1684911_SM5976.pdf" orientation="portrait" id="d37e322" position="anchor"/></supplementary-material></sec></body><back><sec id="s0039"><title>Disclosure statement</title><p>The authors declare no competing financial interest.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Abramovici</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gee</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Topham</surname><given-names>MK</given-names></name></person-group>
<article-title>Diacylglycerol kinases as sources of phosphatidic acid</article-title>.
<source>Biochim Biophys Acta</source>
<year>2009</year>;<volume>1791</volume>:<fpage>942</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19264149</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name></person-group>
<article-title>Role of
diacylglycerol kinases in T cell development and function</article-title>. <source>Crit
Rev Immunol</source>
<year>2013</year>;<volume>33</volume>:<fpage>97</fpage>&#x02013;<lpage>118</lpage>.<pub-id pub-id-type="pmid">23582058</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merida</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Avila-Flores</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Merino</surname><given-names>E</given-names></name></person-group>
<article-title>Diacylglycerol kinases: at the hub of cell signalling</article-title>.
<source>Biochem J</source>
<year>2008</year>;<volume>409</volume>:<fpage>1</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">18062770</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakane</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Imai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kai</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinases: why so many of them?</article-title>
<source>Biochim Biophys Acta</source>
<year>2007</year>;<volume>1771</volume>:<fpage>793</fpage>&#x02013;<lpage>806</lpage>.<pub-id pub-id-type="pmid">17512245</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldanzi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bettio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Malacarne</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Graziani</surname><given-names>A</given-names></name></person-group>
<article-title>Diacylglycerol kinases: shaping diacylglycerol and phosphatidic acid
gradients to control cell polarity</article-title>. <source>Front Cell Dev Biol</source>
<year>2016</year>;<volume>4</volume>:<fpage>140</fpage>.<pub-id pub-id-type="pmid">27965956</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tangye</surname><given-names>SG</given-names></name></person-group>
<article-title>XLP:
clinical features and molecular etiology due to mutations in sh2d1a encoding
sap</article-title>. <source>J Clin Immunol</source>
<year>2014</year>;<volume>34</volume>:<fpage>772</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25085526</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldanzi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pighini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bettio</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sap-mediated inhibition of diacylglycerol kinase alpha regulates
TCR-induced diacylglycerol signaling</article-title>. <source>J Immunol</source>
<year>2011</year>;<volume>187</volume>:<fpage>5941</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">22048771</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruffo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Malacarne</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Larsen</surname><given-names>SE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of diacylglycerol kinase &#x003b1; restores restimulation-induced cell
death and reduces immunopathology in XLP-1</article-title>. <source>Sci Transl
Med</source>
<year>2016</year>;<volume>8</volume>:<fpage>321</fpage>&#x02013;<lpage>327</lpage>.</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velnati</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ruffo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Massarotti</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of a novel DGKalpha inhibitor for XLP-1 therapy by virtual
screening</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>164</volume>:<fpage>378</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">30611057</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacchiocchi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Baldanzi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Carbonari</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Activation of alpha-diacylglycerol kinase is critical for the mitogenic
properties of anaplastic lymphoma kinase</article-title>. <source>Blood</source>
<year>2005</year>;<volume>106</volume>:<fpage>2175</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">15928040</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanagisawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yasuda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kai</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinase alpha suppresses tumor necrosis factor-alpha-induced
apoptosis of human melanoma cells through NF-kappaB activation</article-title>.
<source>Biochim Biophys Acta</source>
<year>2007</year>;<volume>1771</volume>:<fpage>462</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">17276726</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldanzi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cutrupi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chianale</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinase-alpha phosphorylation by Src on Y335 is required for
activation, membrane recruitment and Hgf-induced cell motility</article-title>.
<source>Oncogene</source>
<year>2008</year>;<volume>27</volume>:<fpage>942</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">17700527</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filigheddu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cutrupi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Porporato</surname><given-names>PE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinase is required for Hgf-induced invasiveness and
anchorage-independent growth of mda-mb-231 breast cancer cells</article-title>.
<source>Anticancer Res</source>
<year>2007</year>;<volume>27</volume>:<fpage>1489</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">17595766</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rainero</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Caswell</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Muller</surname><given-names>PA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinase alpha controls RCP-dependent integrin trafficking to
promote invasive migration</article-title>. <source>J Cell Biol</source>
<year>2012</year>;<volume>196</volume>:<fpage>277</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">22270919</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeishi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Taketomi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shirabe</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression
by activation of Ras&#x02013;Raf&#x02013;MEK&#x02013;ERK pathway</article-title>. <source>J Hepatol</source>
<year>2012</year>;<volume>57</volume>:<fpage>77</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">22425622</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Ayuso</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Daza-Martin</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Martin-Perez</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinase alpha promotes 3D cancer cell growth and limits drug
sensitivity through functional interaction with Src</article-title>.
<source>Oncotarget</source>
<year>2014</year>;<volume>5</volume>:<fpage>9710</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">25339152</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rainero</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cianflone</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Porporato</surname><given-names>PE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The diacylglycerol kinase alpha/atypical PKC/beta1 integrin pathway in
SDF-1alpha mammary carcinoma invasiveness</article-title>. <source>PLoS One</source>
<year>2014</year>;<volume>9</volume>:<fpage>e97144</fpage>.<pub-id pub-id-type="pmid">24887021</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Differential gene and protein expression in primary breast malignancies and
their lymph node metastases as revealed by combined cDNA microarray and tissue
microarray analysis</article-title>. <source>Cancer</source>
<year>2004</year>;<volume>100</volume>:<fpage>1110</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">15022276</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mocellin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Belluco</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Gene expression profile of primary gastric cancer: towards the prediction
of lymph node status</article-title>. <source>Ann Surg Oncol</source>
<year>2007</year>;<volume>14</volume>:<fpage>1058</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">17106627</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Floyd</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Diacylglycerol kinase &#x003b1; is a critical signaling node and novel therapeutic
target in glioblastoma and other cancers</article-title>. <source>Cancer Discov</source>
<year>2013</year>;<volume>3</volume>:<fpage>782</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">23558954</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kefas</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Floyd</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Comeau</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A miR-297/hypoxia/DGK-&#x003b1; axis regulating glioblastoma
survival</article-title>. <source>Neuro Oncol</source>
<year>2013</year>;<volume>15</volume>:<fpage>1652</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">24158111</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purow</surname><given-names>B</given-names></name></person-group>
<article-title>Molecular
pathways: targeting diacylglycerol kinase alpha in cancer</article-title>. <source>Clin
Cancer Res</source>
<year>2015</year>;<volume>21</volume>:<fpage>5008</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26420856</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sakane</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kanoh</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Walsh</surname><given-names>JP</given-names></name></person-group>
<article-title>Selectivity
of the diacylglycerol kinase inhibitor
3-[2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidinyl)ethyl]-2,
3-dihydro-2-thioxo-4(1h)quinazolinone (r59949) among diacylglycerol kinase
subtypes</article-title>. <source>Biochem Pharmacol</source>
<year>2000</year>;<volume>59</volume>:<fpage>763</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">10718334</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sasaki</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Evaluations of the selectivities of the diacylglycerol kinase inhibitors
r59022 and r59949 among diacylglycerol kinase isozymes using a new non-radioactive assay
method</article-title>. <source>Pharmacology</source>
<year>2013</year>;<volume>92</volume>:<fpage>99</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">23949095</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boroda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Niccum</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Raje</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Dual activities of ritanserin and r59022 as DGK&#x003b1; inhibitors and serotonin
receptor antagonists</article-title>. <source>Biochem Pharmacol</source>
<year>2017</year>;<volume>123</volume>:<fpage>29</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">27974147</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaulton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hersey</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nowotka</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The ChEMBL database in 2017</article-title>. <source>Nucleic Acids
Res</source>
<year>2017</year>;<volume>45</volume>:<fpage>D945</fpage>&#x02013;<lpage>D954</lpage>.<pub-id pub-id-type="pmid">27899562</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leysen</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Gommeren</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Van Gompel</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Receptor-binding properties in&#x000a0;vitro and in&#x000a0;vivo of ritanserin: a very
potent and long acting serotonin-S2 antagonist</article-title>. <source>Mol
Pharmacol</source>
<year>1985</year>;<volume>27</volume>:<fpage>600</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">2860558</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawkins</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Skillman</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Nicholls</surname><given-names>A</given-names></name></person-group>
<article-title>Comparison
of shape-matching and docking as virtual screening tools</article-title>. <source>J Med
Chem</source>
<year>2007</year>;<volume>50</volume>:<fpage>74</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">17201411</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muchmore</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Souers</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Akritopoulou-Zanze</surname><given-names>I</given-names></name></person-group>
<article-title>The use of
three-dimensional shape and electrostatic similarity searching in the identification of
a melanin-concentrating hormone receptor 1 antagonist</article-title>. <source>Chem Biol
Drug Des</source>
<year>2006</year>;<volume>67</volume>:<fpage>174</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">16492165</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kunii</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sakuma</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A novel diacylglycerol kinase &#x003b1;-selective inhibitor, CU-3, induces cancer
cell apoptosis and enhances immune response</article-title>. <source>J Lipid
Res</source>
<year>2016</year>;<volume>57</volume>:<fpage>368</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">26768655</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baell</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Holloway</surname><given-names>GA</given-names></name></person-group>
<article-title>New
substructure filters for removal of pan assay interference compounds (pains) from
screening libraries and for their exclusion in bioassays</article-title>. <source>J Med
Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>2719</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">20131845</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavagno</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gunella</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bardelli</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Anti-inflammatory drugs and tumor necrosis factor-alpha production from
monocytes: role of transcription factor NF-kappa B and implication for rheumatoid
arthritis therapy</article-title>. <source>Eur J Pharmacol</source>
<year>2004</year>;<volume>501</volume>:<fpage>199</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">15464079</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talmon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rossi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pastore</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human
monocytes/macrophages</article-title>. <source>Br J Pharmacol</source>
<year>2018</year>;<volume>175</volume>:<fpage>113</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">29057467</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Omega</collab></person-group>, version 2.4.6; OpenEye Scientific Software:
Santa Fe, NM. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.eyesopen.com">http://www.eyesopen.com</ext-link></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawkins</surname><given-names>PCD</given-names></name>, <name name-style="western"><surname>Skillman</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Warren</surname><given-names>GL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Conformer generation with omega: algorithm and validation using high
quality structures from the Protein Databank and Cambridge Structural
Database</article-title>. <source>J Chem Inf Model</source>
<year>2010</year>;<volume>50</volume>:<fpage>572</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">20235588</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawkins</surname><given-names>PCD</given-names></name>, <name name-style="western"><surname>Nicholls</surname><given-names>A</given-names></name></person-group>
<article-title>Conformer
generation with omega: learning from the data set and the analysis of
failures</article-title>. <source>J Chem Inf Model</source>
<year>2012</year>;<volume>52</volume>:<fpage>2919</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">23082786</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneidman-Duhovny</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dror</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Inbar</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pharmagist: a webserver for ligand-based pharmacophore
detection</article-title>. <source>Nucleic Acids Res</source>
<year>2008</year>;<volume>36</volume>:<fpage>W223</fpage>&#x02013;<lpage>228</lpage>.<pub-id pub-id-type="pmid">18424800</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Wermuth</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Aldous</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Raboisson</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rognan</surname><given-names>D</given-names></name></person-group>
<source>The practice of
medicinal chemistry</source>. <edition>4th ed</edition>
<publisher-loc>London,
UK</publisher-loc>: <publisher-name>Academic Press</publisher-name>;
<year>2015</year>.</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Urruticoechea</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Larsen</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Sejer
Pedersen</surname><given-names>D</given-names></name></person-group>
<article-title>A scalable
method for regioselective 3-acylation of 2-substituted indoles under basic
conditions</article-title>. <source>J Org Chem</source>
<year>2015</year>;<volume>80</volume>:<fpage>471</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">25469854</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakane</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mizuno</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Komenoi</surname><given-names>S</given-names></name></person-group>
<article-title>Diacylglycerol kinases as emerging potential drug targets for a variety
of diseases: an update</article-title>. <source>Front Cell Dev Biol</source>
<year>2016</year>;<volume>4</volume>:<fpage>82</fpage>.<pub-id pub-id-type="pmid">27583247</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franks</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Purow</surname><given-names>BW</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The ligand binding landscape of diacylglycerol kinases</article-title>.
<source>Cell Chem Biol</source>
<year>2017</year>;<volume>24</volume>:<fpage>870</fpage>&#x02013;<lpage>80.e5</lpage>.<pub-id pub-id-type="pmid">28712745</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The &#x003b6; isoform of diacylglycerol kinase plays a predominant role in
regulatory T cell development and TCR-mediated ras signaling</article-title>.
<source>Sci Signal</source>
<year>2013</year>;<volume>6</volume>:<fpage>ra102</fpage>.<pub-id pub-id-type="pmid">24280043</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu-Sekine</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Goldschmidt</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Raben</surname><given-names>DM</given-names></name></person-group>
<article-title>DGK-&#x003b8;:
structure, enzymology, and physiological roles</article-title>. <source>Front Cell Dev
Biol</source>
<year>2016</year>;<volume>4</volume>:<fpage>101</fpage>.<pub-id pub-id-type="pmid">27683659</pub-id></mixed-citation></ref></ref-list></back></article>